NCT03078582 - Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

March 28, 2018

Study Completion Date

March 28, 2018

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

Zilucoplan (RA101495)

0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC

Trial Locations (12)

Investigative Site, Gosford

Investigative Site, Parkville

Investigative Site, Toronto

Investigative Site, Copenhagen

Investigative Site, Helsinki

Investigative Site, Essen

Investigative Site, Ulm

Investigative Site, Budapest

Investigative Site, Christchurch

Investigative Site, Hamilton

Investigative Site, Leeds

Investigative Site, London